Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis

Journal of Clinical Gastroenterology

Volumn 45, Issue 9, 2011, Pages 818-823

  Lim, Seng Gee ^a,b,c   Aung, Myat Oo ^a   Mak, Belinda ^a   Sutedja, Dede ^a   Lee, Yin Mei ^a   Lee, Guan Huei ^a   Fernandes, Mark ^a   Low, How Cheng ^a   Lai, Vincent ^a   Dan, Yock Young ^a,c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

adefovir; antiviral therapy; chronic hepatitis B; cirrhosis; decompensated cirrhosis; hepatocellular carcinoma; lamivudine; liver failure; liver transplantation; viral resistance

Indexed keywords

ADEFOVIR; LAMIVUDINE;

ADULT; ARTICLE; ASCITES; BRAIN DISEASE; CHILD-PUGH SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END S STAGE LIVER DISEASE SCORE; MORTALITY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADENINE; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHONIC ACIDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052944151     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318214ab5d     Document Type: Article

References (11)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005; 34(suppl 1):S1-S3. (Pubitemid 43197742)
2. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
3. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207-210. (Pubitemid 30033708)
4. Lim SG, Aung MO, Mak B, et al. Low Risk of Multiresistant HBV in a Follow up Study of Lamivudine with Adefovir Switch Strategy. Boston, MA, USA: American Association for Study of Liver Disease; 2009. Abstract 474.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
6. Lindh M, Gonzalez JE, Norkrans G, et al. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Methods. 1998;72:163-174. (Pubitemid 28306959)
7. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-1635.
8. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433-439. (Pubitemid 34520771)
9. Tseng PL, Lu SN, Tung HD, et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005;12:386-392.
10. Chan HL, Chim AM, Lau JT, et al. Evaluation of model for endstage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol. 2006;101:1516-1523. (Pubitemid 43980625)
11. Liaw YF, Lee CM, Chien RN, et al. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006; 13:250-255.